Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.
Lymphoid deficiency after allogeneic hematopoietic cell transplantation (HCT) results in increased susceptibility to infection; however, transplantation of mature lymphocytes frequently results in a serious complication known as graft-versus-host disease (GVHD). Here we demonstrate in mice that both congenic as well as allogeneic transplantation of low numbers of highly purified common lymphoid progenitors (CLPs)-a rare population of lymphoid-lineage-committed bone marrow cells-accelerates immune reconstitution after lethal irradiation and rescue with hematopoietic stem cells (HSCs). After congenic transplantation, 3 x 10(3) CLPs protected against murine cytomegalovirus (MCMV) infection at a level roughly equivalent to 107 unfractionated lymph node cells. In the allogeneic model of matched unrelated donor HSC transplantation, cotransplantation of 3 x 10(3) CLPs protected thymus-bearing as well as thymectomized hosts from MCMV infection and attenuated disease severity. Immunohistochemistry in combination with antibody depletion of T and natural killer (NK) cells confirmed that CLP-derived as well as residual host lymphocytes contribute to antiviral protection. Importantly, transplantation of allogeneic CLPs provided a durable antiviral immunity without inducing GVHD. These data support the potential for composing grafts with committed progenitors to reduce susceptibility to viral infection following HCT.
Arber
Caroline
C
Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA.
BitMansour
Andrew
A
Sparer
Timothy E
TE
Higgins
John P
JP
Mocarski
Edward S
ES
Weissman
Irving L
IL
Shizuru
Judith A
JA
Brown
Janice M Y
JM
D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology; D016026:Bone Marrow Transplantation; D019070:Cell Lineage; D002469:Cell Separation; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control*; D004198:Disease Susceptibility; D006086:Graft vs Host Disease / Q000517:prevention & control; D006183:H-2 Antigens / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D016867:Immunocompromised Host; D007694:Killer Cells, Natural / Q000276:immunology; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology; D008212:Lymphocyte Depletion; D016131:Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation*; D051379:Mice; D020297:Mice, Congenic; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011828:Radiation Chimera; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013934:Thymectomy; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D006183:H-2 Antigens